INTRODUCTION {#s1}
============

Stereotactic radiotherapy (SRT), including Cyberknife SRT, is used to treat patients with primary and metastatic brain tumors \[[@R1]--[@R3]\], whose most common late side effect is brain radiation necrosis\[[@R4]--[@R6]\]. Until now, research on tolerated dose of hypofractionated SRT for brain tumors is limited, especially those about the influencing and predicting factors of brain radiation necrosis post Cyberknife radiosurgery. Here we aimed to address this issue by a retrospective analysis and a reference dose for brain tumor patients undergoing Cyberknife therapy was established. Our results also provided advice on how to reduce the risk of brain radiation necrosis.

RESULTS {#s2}
=======

Occurrence of brain radiation necrosis {#s2_1}
--------------------------------------

Brain necrosis occurred in 12 participants (9 males and 3 females) aged 31-70 (median: 54.5). A total of 12 targets were found representing with necrosis with a rate of 11.54%. Among these 12 cases, 1 had primary brain lymphoma, 1 brain metastases from stomach cancer, 1 brain metastases from kidney cancer, 1 brain metastases from small cell lung cancer, 1 brain metastases from esophagus cancer, and 7 brain metastases from non-small cell lung cancer. Four patients had received whole brain radiotherapy, including 3 were prescribed a dose of 30 Gy/10f, and 1 a dose of 46 Gy/23f. For all the targets treated with Cyberknife, the median treatment volume was 5756.91 mm^3^ (2603.68-16250.10 mm^3^), the median radiation dose 2800 cGy (2000-4000 cGy), the median isodose line 77.5% (68-82%), the median number of fractions 2 (1-4), and the median biologically equivalent prescription dose 7920 cGy (6930-13110 cGy; for those who had received whole brain radiotherapy, the value of BED was obtained by summarizing the BEDs in these two treatments). After Cyberknife therapy it took a median of 14 months (5-24 months) for brain radiation necrosis to develop. See Table [1](#T1){ref-type="table"} for details.

###### Characteristics of the cases of radiation necrosis

  Cases     Age (years old)   Gender   Lesions             Location                  Tracing          WBRT       Target volume (mm^3^)   Dose(cGy)   Dose line (%)   Fraction (f)   BED tumor   BED brain   Time of REP after treatment(Months)
  --------- ----------------- -------- ------------------- ------------------------- ---------------- ---------- ----------------------- ----------- --------------- -------------- ----------- ----------- -------------------------------------
  Case 1    53                Male     NSCLC               Left parietal occipital   skull tracking   No         9091.04                 3600        73              3              7920        25200       7
  Case 2    70                Female   NSCLC               Right parietal            skull tracking   No         6616.31                 3200        75              2              8320        28800       15
  Case 3    31                Female   NSCLC               Right cerebellar          skull tracking   No         2771.79                 2300        79              1              7590        28750       12
  Case 4    53                Female   NSCLC               Right cerebellar          skull tracking   No         13562.74                3000        77              2              7500        25500       21
  Case 5    47                Male     NSCLC               Left occipital lobe       skull tracking   30Gy/10f   4897.5                  2000        82              2              7900        19500       10
  Case 6    47                Male     SCLC                Left temporal lobe        skull tracking   30Gy/10f   4621.61                 2600        77              2              9880        27000       15
  Case 7    58                Male     Lymphoma            Left parietal             skull tracking   46Gy/23f   16250.1                 2300        82              1              13110       37050       5
  Case 8    65                Male     NSCLC               Right parietal            skull tracking   30Gy/10f   2603.68                 2300        82              1              12390       36750       24
  Case 9    64                Male     Esophageal Cancer   Right parietal            skull tracking   No         11221.52                3600        78              3              7920        25200       14
  Case 10   66                Male     NSCLC               Left thalamus             skull tracking   No         7631.72                 3300        68              3              6930        21450       11
  Case 11   49                Male     Kidney cancer       Brain stem                skull tracking   No         3004.19                 4000        74              4              8000        24000       16
  Case 12   56                Male     Gastric Cancer      Left cerebellar           skull tracking   No         4194.93                 2300        81              1              7590        28750       14

Factors associating with brain radiation necrosis {#s2_2}
-------------------------------------------------

The results of the logistic regression showed that combination with whole brain radiotherapy, fractions, and BED were significantly associated with development of brain radiation necrosis in the model, and thus able to contribute to the development. See Table [2](#T2){ref-type="table"} for details.

###### Logistic regression analysis for radiation necrosis

  Factors                          Regression coefficient   Wald value   RR value       95%CI             *P* value
  -------------------------------- ------------------------ ------------ -------------- ----------------- -----------
  Female vs. male                  −0.127                   0.01428      0.881          0.109-7.085       0.905
  Age                              −0.0177                  0.239        0.982          0.915-1.055       0.624
  Diabetes                         0.792                    0.327        2.207          0.146-33.282      0.567
  Cardio-cerebrovascular disease   −5.178                   0.372        0.00564        0.000-94696.156   0.542
  Without or with WBRT             −15.764                  4.025        0.0000000142   0.000-0.695       0.0448
  Target volume                    0.00000118               0.030        1.000          0.999-1.001       0.862
  Dose                             0.0169                   0.000316     0.983          0.152-6.342       0.985
  Dose line                        −0.0463                  0.189        0.955          0.775-1.177       0.664
  Fraction                         −4.075                   4.521        0.0170         0.000397-0.727    0.00335
  BED                              0.00881                  5.311        1.009          1.001-1.016       0.0212

Predictor of brain radiation necrosis {#s2_3}
-------------------------------------

MedCalc software was used to create ROC curves, and factors included BED, combination with whole brain radiation, and fractions (Figure [1](#F1){ref-type="fig"}). The areas under the ROC curves were 0.892±0.0335, 0.650±0.0717, and 0.712±0.0637 respectively, suggesting that BED had more predictive value for brain radiation necrosis than combination with whole brain radiation and fractions. Moreover, the ROC curve analysis showed the BED threshold was 7410 cGy for brain radiation necrosis, and the sensitivity and specificity were well balanced (Table [3](#T3){ref-type="table"}). For the sake of clinical practicability, we further calculated the prescription dose in 1-5 fractions on the basis of the threshold values, and recommended dosages to avoid brain radiation necrosis for clinical reference was shown in Table [4](#T4){ref-type="table"}.
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###### Multiple factors in ROC curve analysis

                                     AUC            95%CI         z statistic   *P* value (Area=0.5)   Associated criterion   Sensitivity   Specificity
  ---------------------------------- -------------- ------------- ------------- ---------------------- ---------------------- ------------- -------------
  With or without WBRT(0:no/1:yes)   0.650±0.0717   0.551-0.741   2.098         0.0359                 \>0                    33.33         96.74
  Fraction(f)                        0.712±0.0637   0.615-0.797   3.335         0.0009                 \<=2                   66.67         66.30
  BED(cGy)                           0.892±0.0335   0.816-0.945   11.710        \<0.0001               \>7410                 91.67         84.78

###### Recommended dosages for avoiding brain radiation necrosis in clinical practice

  Fractions   Dose (Gy/F)
  ----------- -------------
  1F          22.68
  2F          14.89
  3F          11.49
  4F          9.44
  5F          8.16

DISCUSSION {#s3}
==========

Brain radiation necrosis is caused by white matter injury characterized by loss of oligodendrocytes, along with demyelination (Glial Injury Hypothesis) \[[@R14], [@R15]\] or vasogenic edema (Vascular Injury Hypothesis) \[[@R16]--[@R18]\]. Radiation damage to glial cells and vascular endothelial cells can lead to various late effects in the brain, and the extent of the damage depends on the biological dose. This study showed that BED, combination with whole brain radiotherapy, and fractions would contribute to brain radiation necrosis following Cyberknife therapy. BED was higher in patients who had received whole brain radiotherapy as a result of adding together the doses of two treatment regimens. Brain belongs to late-responding tissues, and are found to have low values of α/β ratio, and are more susceptible to a single, high dose of radiation. If the total dose keeps unchanged, fewer fractions will lead to a higher BED, thus increasing the risk of brain necrosis. The ROC curve analysis further confirmed the founding from the logistic regression analysis.

Varying doses are always adopted during Cyberknife therapy for various patients with different treatment plans and treatment volumes. For patients with systemic metastases, palliative care with low-dose radiation was usually given to obtain symptom relief; whereas for patients with a single brain metastasis, a higher dose might have been prescribed. Furthermore, tumours with larger volume usually result in palliative treatment. This study created a good chance for research on radiation tolerance of brain tissue with the various prescription doses, and results showed that the treatment volume did not appear to affect the development of brain radiation necrosis.

The rate of brain radiation necrosis was 11.54%, consistent with previous research \[[@R19], [@R20]\]. Furthermore, we analyzed the factors affecting and predicting brain radiation necrosis, established the threshold value for brain radiation necrosis and given a recommended prescription dose \[[@R21], [@R22]\]. More importantly, the study fills a gap in the research on the tolerated dose of hypofractionated SRT for brain tumours, and are also clinically important in terms of avoiding the occurrence of brain radiation necrosis following Cyberknife SRT.

In conclusion, by analyzing the brain necrosis cases, we explored various factors that may affect radiation necrosis in the brain, and the tolerated dose of hypofractionated radiotherapy for brain tumours. A reference dose level has been established to reduce the toxicity of Cyberknife therapy. We believe this study has paved the way for future research that will produce more substantial evidence to prevent brain radiation necrosis following Cyberknife SRT and improve treatment of brain cancer using Cyberknife.

MATERIALS AND METHODS {#s4}
=====================

Patient information {#s4_1}
-------------------

The study was carried out in accordance with the institutional ethical guidelines and the use of patient information was approved by the Medical Ethics Committee of Tianjin Medical University Cancer institute and Hospital. Every patient involved in the study was asked to sign a piece of written informed consent which has been approved by the ethics committee of Tianjin Medical University Cancer institute and Hospital. The study was conducted according to the principles expressed in the Declaration of Helsinki. A total of 94 patients (mean age 51.5, range 6-85; 58 males and 36 females) with primary or metastatic brain tumours who had been treated with Cyberknife between September 2006 and October 2011 were collected and analyzed retrospectively. The inclusion criteria included primary or metastatic brain tumours, usage of Cyberknife SRT to treat brain tumours, follow-up of at least two-year, diagnosis of radiation necrosis confirmed by imaging or pathological examination. There were 104 targets, including 81 targets in 81 patients with brain metastases and 23 targets in 13 patients with primary brain tumours. Five patients (7 targets) received whole brain radiotherapy before Cyberknife SRT, among whom 4 (6 targets) were given a dose of 30 Gy/10f; and 1 (1target) 46 Gy/23f. Skull based tracking was used, together with a 60-87% isodose line (median: 79%), a dose of 1200-4500 cGy (median: 2550 cGy) and a BED of 2380-13110 cGy (median: 5130cGy) in 1-8 fractions (median: 3). BED=nd × (1+d/10); n: fraction, d: the dose of one fraction, α/β=10. See Table [5](#T5){ref-type="table"} for details.

###### Clinical characteristics of patients

  Characteristics                          Values
  ---------------------------------------- ---------------------------
  Number of cases (*n*)                    94
  Number of targets (*n*)                  104
  Gender                                   
   Male                                    58
   Female                                  36
  Mean age in years (range)                51.5 (6-85)
  Targets                                  
   Primary                                 23
   Metastatic                              81
  Combined with WBRT(Targets)              
   Yes                                     7
   No                                      97
  Mean treatment volume in mm^3^ (range)   7805.78 (136.21-92760.70)
  Mean dose line in percentage (range)     79 (60-87)
  Mean dose in cGy (range)                 2550.00 (1200-4500)
  Mean fraction in f (range)               3 (1-8)
  Mean BED-tumor in cGy (range)            5130 (2380-13110)
  Radiation encephalopathy (targets)       
   Yes                                     12
   No                                      92

Diagnosis of brain radiation necrosis {#s4_2}
-------------------------------------

Comprehensive imaging is the most realistic and most frequently used method in the diagnosis of brain radiation necrosis \[[@R7]--[@R9]\]. While pathological examination, although known as the golden standard, was unachievable due to the following reasons. Firstly, many of the brain tumors treated with Cyberknife are located near the skull base or in the important functional areas, resulting in impossibility of surgical resection or stereotactic puncture. Secondly, patients with history of Cyberknife treatment, especially those with multiple lesions, usually rejected a puncture because it is the last choice in clinical practice to perform puncture biopsy of every single lesion. Furthermore, even a stereotactic puncture may not be able to completely display the pathological characteristics of the involved tissue.

Therefore comprehensive imaging is the most realistic and frequently used method in the diagnosis of brain radiation necrosis\[[@R7]--[@R9]\], and we chose to make the diagnosis upon patients\' medical history, signs and symptoms, along with results of various imaging approaches such as MRI, nuclear magnetic resonance spectroscopy, and PET-CT \[[@R10]--[@R13]\] in this study. MRI scan and resonance spectroscopy were conducted first, and PET-CT further introduced if the diagnosis cannot be confirmed. Briefly, most brain necrosis showed irregular shape in MRI with hypointense on T1WI and hyperintense on T2WI. Moreover, liquefaction necrosis often represented with lower signal intensity on T1WI and higher signal intensity on T2WI. After administration of Gd-DTPA, irregularly enhanced signal without enhanced nodular was obtained in the lesions center, while a large area of edema belt in T1 and T2 signal without enhancement around the lesions. In MRS, Cho, Cr and NAA levels were reduced, and NAA/Cho and NAA/Cr radio decreased. In PET, the metabolic rate of brain radiation necrosis was lower than that of normal brain tissue, resulting in decreased uptake of FDG and defected radioactive imaging in the corresponding region. The diagnosis was all ultimately determined by 3 independent investigators. If a patient had severe symptoms but also indications for surgery, the lesion could be resected and the diagnosis confirmed by histology. In this study, there were 12 patients with brain necrosis, with 1 confirmed by pathology and 11 by imaging.

Follow-up and statistical methods {#s4_3}
---------------------------------

MRI assessment of brain lesions should be conducted regularly 2 months after the Cyberknife radiosurgery; patients should be re-examined once every 3 months within the following one year, and then re-examined if necessary for a maximum of 6 months. If symptoms of intracranial lesions occurred, re-examination should be done immediately. All statistical analyses were executed using SPSS 17.0 software. The level of significance was defined as *P* \< 0.05. Logistic regression was performed to explore associations between brain radiation necrosis and factors including diabetes, cardio-cerebrovascular disease, age, gender, combination with whole brain radiation, prescribed dosage, fractions, isodose line, and BED. MedCalc software was used in ROC curve analysis which included all the statistically significant factors in the logistic regression model, and the threshold values of the factors were estimated.
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